Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-29
2008-04-29
Seaman, Margaret D. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S234500, C514S252010, C514S300000, C546S121000, C544S111000, C544S253000
Reexamination Certificate
active
10524577
ABSTRACT:
Novel pyrazolopyridine derivative compounds are disclosed and their use as pharmaceutical agents, in particular their use as TGF-beta signal transduction inhibitors useful in the treatment of cancer and other disease states influenced by TGF beta.
REFERENCES:
patent: 2001139575 (2001-05-01), None
patent: WO 02 062787 (2002-08-01), None
patent: WO 02 062794 (2002-08-01), None
patent: WO 02 066462 (2002-08-01), None
patent: WO 02 094833 (2002-11-01), None
Dermer (Bio/Technology, 1994, 12:320).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, pp. 1-6).
Beight Douglas Wade
Bonjouklian Rosanne
Liao Junkai
McMillen William Thomas
Parkhurst Brandon Lee
Eli Lilly and Company
Hostettler Danica L.
Rahmani Niloofar
Seaman Margaret D.
Tucker Tina M.
LandOfFree
Pyrazolopyridine derivatives as pharmaceutical agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyridine derivatives as pharmaceutical agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyridine derivatives as pharmaceutical agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3916509